Kfh Kuratorium Fuer Dialyse Und Nierentransplantation e.V.
- Address
- Haus 54, Delitzscher Strasse 141, Eutritzsch, 04129 Leipzig, Germany
KfH Kuratorium für Dialyse und Nierentransplantation e.V.
KfH Kuratorium für Dialyse und Nierentransplantation e.V. is a specialized research institution focused on advancing treatment options for patients with end-stage kidney disease (ESKD) and those requiring dialysis support. The center demonstrates expertise in investigating novel therapeutic approaches that address both renal replacement therapy and associated cardiovascular complications in the dialysis population.
- Cardiovascular disease management in end-stage kidney disease patients
- Anti-inflammatory therapies for dialysis populations
- Dose-finding studies for renal therapeutics
The research center actively participates in innovative clinical trials examining atherosclerotic cardiovascular disease in patients undergoing maintenance dialysis. Their work includes evaluating targeted biological therapies aimed at reducing inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP), addressing the critical intersection between chronic kidney disease, systemic inflammation, and cardiovascular risk in this vulnerable patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1CSL Behring LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kfh Kuratorium Fuer Dialyse Und Nierentransplantation e.V.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clazakizumab | 1 | Unknown | 2023-07-17 | 2023-07-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.